ERBB2 and cancer: The paper further emphasizes that intestinal bacteria and their metabolites can directly or indirectly regulate several signaling pathways relevant to cancer therapy, including VEGFR, EGFR, and HER2, thereby influencing cancer growth, metastasis, and therapeutic responses (Yu et al. 2020; Tao et al. 2019).